Cell Genesys Inc.  (CEGE) Trade Now »     Rate CEGE  -  Discuss CEGE  -  Add to Watch List        

Synta Pharmaceuticals (SNTA)may look like the typical American biotech company: A promising phaseIII compound, which is, of course, partnered with a pharma giant, twoagents in early clinical stages, a list of failed trials, and analarming cash burn rate.<!--more--> Nonetheless, the story behind the company’slead product, elesclomol, is shaping up as one of the most interestingevents in oncology in recent years. Elesclomol is currently in aregistrational phase III trial for metastatic melanoma, a majorachievement by itself, however, if successful, this trial will mark twoevents on a historic